Emerging reports suggest that inhibition of TIGIT(T cell immunoreceptor with Ig and ITIM domains) has shown promise in enhancing anti-tumor immunity by complementing the PD-L1/PD-1 axis. The gene discussed is CD274; the disease is neoplasm.